The role of Brønsted and Lewis acidity in the green synthesis of homopropargyl alcohols over HZSM-5

Ahighly efficient and simple reaction under exceptionally mild conditions is shown for the synthesis of biologically and pharmaceutically active molecules of homopropargyl alcohol using HZSM-5 as the catalyst. Products analyzed by IR, 1H NMR, 13CNMRand GC-MS showed consistent yields of 98 % of the alcohol, even with respective recycles of the regenerated catalyst. The reaction was also carried out with selected mineral acids, acidic oxides and other acidic catalysts to compare reactivity and the influence of the type of acidity involved in the reaction. The results indicate that the presence of both Brønsted and Lewis acidity is beneficial for inducing a high rate of reaction when compared to systems having either predominantly Brønsted or Lewis acidity.Keywords: Homopropargyl, zeolites, HZSM-

Transition metal oxide supported on alumina catalysts: a comparative study for the hydrogenation of octanal

Monometallic (10 wt.%) Co, Ni and Cu nanoparticles supported on alumina catalysts were prepared using an ultrasonic impregnation- cavitation method and characterized using ICP, XRD, physisorption, chemisorption and temperature programmed techniques. The copper catalyst showed higher metal dispersion and greater hydrogen and CO chemisorption capacity when compared to the nickel and cobalt catalysts. Hydrogenation of octanal carried out in a continuous flow high pressure fixed bed reactor showed that the rate of reaction and turnover number of octanol depended on the amount of hydrogen chemisorbed. The copper catalyst showed the lowest activation energy, as well as best catalytic activity. The Cu-Al catalyst which showed higher metal dispersion and low acidity, showed the highest selectivity towards octanol with no C24 acetal formation, when compared to the Ni-Al and Co-Al catalysts.Keywords: Octanal hydrogenation, octanol, copper, nickel, cobal

Tipifarnib prevents development of hypoxia-induced pulmonary hypertension

Aims. RhoB plays a key role in the pathogenesis of hypoxia - induced pulmonary hypertension. Farne sylated RhoB promotes growth responses in cancer cells and we investigated whether inhibition of protein farnesylation will have a protective effect. Methods and Results. The analysis of l ung tissues from rodent models and pulmonary hypertensive patients showed increased levels of protein farnesylation. Oral farnesyltransferase inhibitor tipifarnib prevented development of hypoxia - induced pulmonary hypertension in mice. Tipifarnib reduced hypoxia - induced vascular cell proliferation, increased endothelium - dependent vasodilatation and reduced vasoconstriction of intrapulmonary arteries without affecting cell viability. Protective effects of tipifarnib were associated with inhibition of Ras and RhoB, actin depolymerisation and increased eNOS expression in vi tro and in vivo . Farnesylated - only RhoB (F - RhoB) increased proliferative responses in cultured pulmonary vascular cells, mimicking the effects of hypoxia, while both geranylgeranylated - only RhoB (GG - RhoB) and tipifarnib had an inhibitory effect. Label - fre e proteomics linked F - RhoB with cell survival, activation of cell cycle and mitochondrial biogenesis. Hypoxia increased and tipifarnib reduced the levels of F - RhoB - regulated proteins in the lung, reinforcing the importance of RhoB as a signalling mediator. Unlike simvastatin, tipifarnib did not increase the expression levels of Rho proteins. Conclusions. Our study demonstrates the importance of protein farnesylation in pulmonary vascular remodeling and provides a rationale for selective targeting of this pa thway in pulmonary hypertension

Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : A modelling study

Publisher Copyright: © 2017 Elsevier LtdBackground The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8–1·1) in 2015, corresponding to 71·1 million (62·5–79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation.publishersversionPeer reviewe

Phase Transition of High-Surface-Area Glycol–Thermal Synthesized Lanthanum Manganite

Cubic and rhombohedral phases of lanthanum manganite were synthesized in a high-pressure reactor. A mixture of La and Mn nitrates with ethylene glycol at a synthesis temperature of 200 °C and a calcination temperature of up to 1000 °C, resulted in a single-phase perovskite, LaMnO3 validated using X-ray diffraction. Significant changes in unit cell volumes from 58 to 353 Å3 were observed associated with structural transformation from the cubic to the rhombohedral phase. This was confirmed using structure calculations and resistivity measurements. Transmission electron microscopy analyses showed small particle sizes of approximately 19, 39, 45, and 90 nm (depending on calcination temperature), no agglomeration, and good crystallinity. The particle characteristics, high purity, and high surface area (up to 33.1 m2/g) of the material owed to the inherent PAAR reactor pressure, are suitable for important technological applications, that include the synthesis of perovskite oxides. Characteristics of the synthesized LaMnO3 at different calcination temperatures are compared, and first-principles calculations suggest a geometric optimization of the cubic and rhombohedral perovskite structures

Phase Transition of High-Surface-Area Glycol–Thermal Synthesized Lanthanum Manganite

Cubic and rhombohedral phases of lanthanum manganite were synthesized in a high-pressure reactor. A mixture of La and Mn nitrates with ethylene glycol at a synthesis temperature of 200 °C and a calcination temperature of up to 1000 °C, resulted in a single-phase perovskite, LaMnO3 validated using X-ray diffraction. Significant changes in unit cell volumes from 58 to 353 Å3 were observed associated with structural transformation from the cubic to the rhombohedral phase. This was confirmed using structure calculations and resistivity measurements. Transmission electron microscopy analyses showed small particle sizes of approximately 19, 39, 45, and 90 nm (depending on calcination temperature), no agglomeration, and good crystallinity. The particle characteristics, high purity, and high surface area (up to 33.1 m2/g) of the material owed to the inherent PAAR reactor pressure, are suitable for important technological applications, that include the synthesis of perovskite oxides. Characteristics of the synthesized LaMnO3 at different calcination temperatures are compared, and first-principles calculations suggest a geometric optimization of the cubic and rhombohedral perovskite structures

Effect of the fuel on the surface VOx concentration, speciation and physico-chemical characteristics of solution combustion synthesised VOx/MgO catalysts for n-octane activation

VOx/MgO catalysts, synthesised via solution combustion synthesis were developed for ODH of n-octane using urea, citric acid, hydrazine hydrate, oxalyldihydrazide and glycine as fuels. The effect of these fuels on influencing defects, surface VOx concentration, basic properties and redox properties using various analytical methods were studied. Notable differences in surface and bulk characteristics of the vanadates were observed due to the fuel employed, affecting conversion of octane and selectivity to ODH products. Glycine as fuel gave best octene selectivity due to ease of reducibility of the VOx species, medium surface basicity, and relatively high concentration of surface oxygen vacancies

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo